What You Need to Know Ahead of The Cigna Group’s Earnings Release

Headquartered in Bloomfield, Connecticut, The Cigna Group (CI) is a global health company focused on improving health and vitality. Through its Cigna Healthcare and Evernorth Health Services businesses, the company serves more than 185 million customer relationships across over 30 markets and jurisdictions. CI has a market capitalization of $74.6 billion.

CI is scheduled to report its Q3 earnings on Thursday, November 5, 2026, before the market opens. Ahead of the release, analysts expect diluted EPS of $7.46, down 4.7% from $7.83 in the year-ago quarter. However, CI has exceeded Wall Street’s EPS estimates in each of the past four quarters, demonstrating a consistent track record of earnings outperformance.

For fiscal 2026, analysts expect CI to report EPS of $30.50, up 2.2% from $29.84 in fiscal 2025. Its EPS is projected to increase another 9.7% to $33.46 in fiscal 2027.

CI stock has declined 5.8% over the past 52 weeks, underperforming both the S&P 500 Index ($SPX), which gained 19.2%, and the State Street Health Care Select Sector SPDR ETF (XLV), which advanced 21% over the same period.

The Cigna Group faces concerns about customer retention and sustained customer growth, with its customer base declining by an average of 8.1% over the past two years. Nevertheless, the company continues to deliver solid underlying results, with revenue growing at an annual rate of 13.8% over the past two years and EPS increasing by 12% annually over the past five years. 

Meanwhile, on October 6, Cigna Healthcare introduced Health Sense, a personalized support model designed to improve patient outcomes and affordability by connecting health information, benefits, costs, and clinical expertise. Projected to reduce inefficient healthcare spending by 10% by 2030, the initiative will initially target customers with oncology and cardiometabolic conditions beginning in early 2027. Following the announcement, CI shares rose 1.1%.

Analysts remain somewhat bullish on CI, with a consensus “Moderate Buy” rating. Of the 23 analysts covering the stock, 14 recommend a “Strong Buy,” three suggest a “Moderate Buy,” and six rate it a “Hold.” The average analyst price target of $342.26 represents a 20.8% premium to the current share price.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.